PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21342228-3 2011 This study was conducted to review sorafenib-associated HSF in Japanese patients, to facilitate improvement of the management of HFS in clinical practice. Sorafenib 35-44 interleukin 6 Homo sapiens 56-59 22406995-0 2012 Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis. Sorafenib 0-9 interleukin 6 Homo sapiens 34-38 22406995-7 2012 Sorafenib also inhibited the phosphorylation of STAT3 induced by IL-6 and sphingosine-1-phosphate (S1P), a recently identified regulator for STAT3, in these tumor cells. Sorafenib 0-9 interleukin 6 Homo sapiens 65-69 21331764-6 2011 In the cells treated with sorafenib, phosphorylation of mitogen-activated protein kinase kinase (MEK) and mitogen-activated protein kinase (MAPK) and also interleukin-6-induced phosphorylation of signal transducer and activator of transcription 3 (STAT3) were inhibited in a dose-dependent manner. Sorafenib 26-35 interleukin 6 Homo sapiens 155-168 34687791-0 2022 Induction of IL-6Ralpha by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma. Sorafenib 55-64 interleukin 6 Homo sapiens 41-45 34687791-6 2022 Depletion of IL-6Ralpha abolished IL-6 induced STAT3 phosphorylation at 705th tyrosine and tumor growth of HCC cells under sorafenib treatment. Sorafenib 123-132 interleukin 6 Homo sapiens 34-38 34687791-8 2022 Depletion of ATF3 or its upstream transcription factor, ATF4, attenuated IL-6Ralpha induction and IL-6 mediated sorafenib resistance. Sorafenib 112-121 interleukin 6 Homo sapiens 98-102 30154433-0 2018 ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib. Sorafenib 102-111 interleukin 6 Homo sapiens 16-19 33432366-0 2021 IL-6 plays a crucial role in epithelial-mesenchymal transition and pro-metastasis induced by sorafenib in liver cancer. Sorafenib 93-102 interleukin 6 Homo sapiens 0-4 33432366-2 2021 However, the role and molecular mechanism of IL-6 in the treatment of sorafenib in liver cancer remain unclear. Sorafenib 70-79 interleukin 6 Homo sapiens 45-49 33432366-3 2021 In the present study, through western blot analysis, Transwell assay, flow cytometric assay, ELISA analysis and immunohistochemistry it was revealed that sorafenib promoted metastasis and induced epithelial-mesenchymal transition (EMT) in liver cancer cells in vitro and in vivo, and significantly increased IL-6 expression. Sorafenib 154-163 interleukin 6 Homo sapiens 308-312 33432366-5 2021 Knocked out IL-6 markedly attenuated the pro-metastasis effect of sorafenib and increased the susceptibility of liver cancer cells to it. Sorafenib 66-75 interleukin 6 Homo sapiens 12-16 32918399-7 2021 Sorafenib also inhibited steatosis-induced fibrogenesis by downregulating COL1A1, TGFB1, PDGF, and TIMP1 and by decreasing protein levels of IL-6, TGF-beta1, and TNF-alpha in fatty spheroids. Sorafenib 0-9 interleukin 6 Homo sapiens 141-145 33061451-0 2020 IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells. Sorafenib 36-45 interleukin 6 Homo sapiens 0-4 33061451-3 2020 The inflammatory factor interleukin 6 (IL-6) plays a role in sorafenib resistance in HCC. Sorafenib 61-70 interleukin 6 Homo sapiens 24-37 33061451-3 2020 The inflammatory factor interleukin 6 (IL-6) plays a role in sorafenib resistance in HCC. Sorafenib 61-70 interleukin 6 Homo sapiens 39-43 33061451-4 2020 However, the mechanism by which IL-6 in LCSCs is involved in the process of HCC sorafenib resistance remains elusive. Sorafenib 80-89 interleukin 6 Homo sapiens 32-36 33061451-9 2020 Finally, a xenograft model was used to evaluate the function of IL-6 in the sorafenib resistance of HCC. Sorafenib 76-85 interleukin 6 Homo sapiens 64-68 33061451-12 2020 Downregulation of IL-6 expression with short hairpin RNA (shRNA) restored sorafenib sensitivity in resistant LCSCs, suggesting the critical roles of IL-6/STAT3 in inducing sorafenib resistance. Sorafenib 74-83 interleukin 6 Homo sapiens 18-22 33061451-12 2020 Downregulation of IL-6 expression with short hairpin RNA (shRNA) restored sorafenib sensitivity in resistant LCSCs, suggesting the critical roles of IL-6/STAT3 in inducing sorafenib resistance. Sorafenib 172-181 interleukin 6 Homo sapiens 18-22 33061451-13 2020 Furthermore, a xenograft tumor model showed that IL-6 downregulation improved the antitumor effect of sorafenib. Sorafenib 102-111 interleukin 6 Homo sapiens 49-53 33061451-14 2020 Conclusion: LCSCs play an important role in sorafenib-resistant HCC, and inhibition of the IL-6/STAT3 signaling pathway improves the antitumor effects of sorafenib against HCC in vitro and in vivo. Sorafenib 154-163 interleukin 6 Homo sapiens 91-95 33061451-15 2020 These findings demonstrate that IL-6 in LCSCs may function as a novel target for combating sorafenib resistance in HCC. Sorafenib 91-100 interleukin 6 Homo sapiens 32-36 32103983-0 2020 LncRNA DANCR Promotes Sorafenib Resistance via Activation of IL-6/STAT3 Signaling in Hepatocellular Carcinoma Cells. Sorafenib 22-31 interleukin 6 Homo sapiens 61-65 32103983-15 2020 Conclusion: Collectively, our study is the first to elucidate the mechanism of DANCR-mediated sorafenib resistance via PSMD10-IL-6/STAT3 signaling axis, which provides a promising target for developing new therapeutic strategy for sorafenib tolerance of HCC. Sorafenib 94-103 interleukin 6 Homo sapiens 126-130 30369518-15 2018 And we found that 786-O RCC cells secrete high IL-6 levels after low dose stimulation with the TKIs sorafenib, sunitinib and pazopanib, inducing activation of AKT-mTOR pathway, NFkappaB, HIF-2alpha and VEGF expression. Sorafenib 100-109 interleukin 6 Homo sapiens 47-51 33855585-0 2022 Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial. Sorafenib 124-133 interleukin 6 Homo sapiens 9-29 33855585-9 2022 CONCLUSION: IL-6 and IL-8 baseline values predicted outcomes of sorafenib-treated patients in this well-characterized prospective cohort of the SORAMIC trial. Sorafenib 64-73 interleukin 6 Homo sapiens 12-16 33273830-0 2020 Erratum: IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Corrigendum]. Sorafenib 45-54 interleukin 6 Homo sapiens 9-13 31771617-15 2019 CONCLUSIONS: The DNMT3b plays a critical role in the IL-6-mediated OCT4 expression and the drug sensitivity of sorafenib-resistant HCC. Sorafenib 111-120 interleukin 6 Homo sapiens 53-57 31771617-17 2019 Findings from this study highlight the significance of IL-6-DNMT3b-mediated OCT4 expressions in future therapeutic target for patients expressing cancer stemness-related properties or sorafenib resistance in HCC. Sorafenib 184-193 interleukin 6 Homo sapiens 55-59 31387809-0 2019 Decreased IL-6 induces sensitivity of hepatocellular carcinoma cells to sorafenib. Sorafenib 72-81 interleukin 6 Homo sapiens 10-14 31387809-3 2019 Therefore, in the present study, we attempted to investigate the effect and mechanisms of IL-6 on sensitivity of HCC cells to sorafenib regarding the cell proliferation and apoptosis. Sorafenib 126-135 interleukin 6 Homo sapiens 90-94 31387809-7 2019 Furthermore, sorafenib significantly inhibited cell proliferation, IL-6 level and activation of p-PI3K/AKT while promoted the cell apoptosis rate and Caspase3 level compared as the control group, which were further promoted by administration of si IL-6. Sorafenib 13-22 interleukin 6 Homo sapiens 67-71 31387809-7 2019 Furthermore, sorafenib significantly inhibited cell proliferation, IL-6 level and activation of p-PI3K/AKT while promoted the cell apoptosis rate and Caspase3 level compared as the control group, which were further promoted by administration of si IL-6. Sorafenib 13-22 interleukin 6 Homo sapiens 248-252 31387809-8 2019 Therefore, downregulating IL-6 could be a potential treatment to increase the cell sensitivity of HCC cells to sorafenib. Sorafenib 111-120 interleukin 6 Homo sapiens 26-30 30154433-4 2018 In this study, we investigated the effect of SASP-related p16/IL6 axis on sorafenib resistance in HCC. Sorafenib 74-83 interleukin 6 Homo sapiens 62-65 30154433-5 2018 Initially, we noticed that HCC cells with a high level of p16/IL6 axis exhibited a low sensitivity to sorafenib. Sorafenib 102-111 interleukin 6 Homo sapiens 62-65 30154433-7 2018 Overexpression of ID1 or IL6 blocking in sorafenib-resistant HCC cells could increase the cytotoxicity of sorafenib. Sorafenib 41-50 interleukin 6 Homo sapiens 25-28 30154433-7 2018 Overexpression of ID1 or IL6 blocking in sorafenib-resistant HCC cells could increase the cytotoxicity of sorafenib. Sorafenib 106-115 interleukin 6 Homo sapiens 25-28 30154433-8 2018 Moreover, SASP-related p16/IL6 axis contributed to the formation of acquired resistance in cells received long-term exposure to sorafenib. Sorafenib 128-137 interleukin 6 Homo sapiens 27-30 30154433-9 2018 In acquired sorafenib-resistant cells, ID1 low expression, p16/IL6 axis up-regulation, and AKT phosphorylation activation were observed. Sorafenib 12-21 interleukin 6 Homo sapiens 63-66 30154433-11 2018 The reversal of sorafenib resistance could be achieved through ID1 overexpression, IL6 blocking, and AKT pathway inhibition. Sorafenib 16-25 interleukin 6 Homo sapiens 83-86 30154433-12 2018 Our study reveals that SASP-related p16/IL6 axis activation is responsible for sorafenib resistance, which will be a novel strategy to prevent the drug resistance. Sorafenib 79-88 interleukin 6 Homo sapiens 40-43 29137334-9 2017 In addition, combined treatment with sorafenib and kahweol markedly induced apoptosis in human lung carcinoma (A549) and breast carcinoma (MDA-MB-361) cells, but not in human normal mesangial cells and human skin fibroblast cells (HSF). Sorafenib 37-46 interleukin 6 Homo sapiens 231-234 26244291-6 2015 Sorafenib significantly inhibited production of TGF-beta1, VEGF, IL-6, IL-8, MCP-1, and TNF-alpha and blocked the activation of migration-related signaling molecules, such as HIF-1alpha, p-STAT3, MMP2, and Ang-1. Sorafenib 0-9 interleukin 6 Homo sapiens 65-69 24833103-10 2014 IL-6 expression was significantly higher in mesenchymal tumors, and knockdown of IL-6 in mesenchymal HCC cell lines increased E-cadherin expression and sensitivity to sorafenib. Sorafenib 167-176 interleukin 6 Homo sapiens 81-85 29100435-2 2017 Experimental Design: IL-6 was disrupted by transcription activator-like effector nucleases (TALEN) in HCCLM3 cells, and was used to evaluate the role of IL-6 on tumor cell proliferation, apoptosis, invasion and key signaling pathways involved in sorafenib and/or IFNalpha therapy. Sorafenib 246-255 interleukin 6 Homo sapiens 21-25 29100435-4 2017 IL-6 could attenuate the anti-proliferation effect by sorafenib and combination therapy but facilitate the pro-apoptosis of the combination therapy and augment the pro-invasive effect induced by single treatment. Sorafenib 54-63 interleukin 6 Homo sapiens 0-4 29100435-5 2017 IL-6 could down-regulate p-STAT3, however up-regulate the p-MEK/p-ERK and NF-kB/iNOS expression, and it also facilitated the promotion on p-JAK2 and p-MEK/p-ERK by either sorafenib or IFN-alpha. Sorafenib 171-180 interleukin 6 Homo sapiens 0-4 29100435-9 2017 Sorafenib and combination therapies are suitable for HCC cells with low or no IL-6 expression confirmed in vivo study. Sorafenib 0-9 interleukin 6 Homo sapiens 78-82 28903416-7 2017 786-O RCC cells secrete high IL-6 levels after low dose stimulation with the TKIs sorafenib, sunitinib and pazopanib, inducing activation of AKT-mTOR pathway, NFkappaB, HIF-2alpha and VEGF expression. Sorafenib 82-91 interleukin 6 Homo sapiens 29-33 27841868-0 2017 Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma. Sorafenib 42-51 interleukin 6 Homo sapiens 75-79 27841868-5 2017 Mechanistically, lncRNA-SRLR directly binds to NF-kappaB and promotes IL-6 transcription, leading to the activation of STAT3 and the development of sorafenib tolerance. Sorafenib 148-157 interleukin 6 Homo sapiens 70-74 27841868-6 2017 A STAT3 inhibitor and IL-6-receptor antagonist both restored the response to sorafenib treatment. Sorafenib 77-86 interleukin 6 Homo sapiens 22-26 27131739-7 2016 Treating EpCAM+/CD133+ cancer stem cells with IL6 receptor blocking antibody or c-Met inhibitor SU11274 both reduced the increase in motility; however SU11274 had greater effect on relieving protection from sorafenib-induced apoptosis. Sorafenib 207-216 interleukin 6 Homo sapiens 46-49